http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020319186-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_20e843db13b2ae4dea539dd10916f294 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-62 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N1-38 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N1-38 |
| filingDate | 2018-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b136f27c35413d74bc9a0fa7b78b9ca1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c594e7687385ba75237299bae1799410 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f79288681842ec53f9c477bc9ded283 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f04ad3585a4cfca8377cc58fe127b4e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0dd9a541c864f50811b8017c5bc47ff |
| publicationDate | 2020-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020319186-A1 |
| titleOfInvention | Markers for diagnosis and prognostic prediction of npc and application thereof |
| abstract | Disclosed are markers for nasopharyngeal carcinoma (NPC) diagnosis and prognostic prediction, and use thereof. The INSL5 level in a plasma sample can be determined by means of ELISA. It was found that the INSL5 plasma level is significantly different between NPC patients and healthy population. The analysis results of a ROC curve show that an area under curve of INSL5 is 0.941, the critical value of the INSL5 level is 2.45 ng/ml, and the sensitivity and specificity thereof are 93.2% and 81.5% respectively. In the healthy cohort, the INSL5 level in EBV-positive plasma is significantly higher than that in EBV-negative plasma. The EBV-negative subjects comprise 34 healthy individuals and 72 NPC patients, and the INSL5 levels are observed to be significantly different between these two cohorts. The results of the ROC curve show that the area under curve of INSL5 is 0.988, the critical value of the INSL5 level is 2.25 ng/ml, and the sensitivity and specificity thereof are 97.2% and 91.2% respectively. Thus, the present disclosure can efficiently distinguish EBV-negative normal people from NPC patients. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111979319-A |
| priorityDate | 2018-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 106.